Neurophyt (Co-CEOs Bin Jun-gil and Kim Dong-hyun), a company specializing in artificial intelligence (AI) for brain disease diagnosis and treatment, announced on the 9th that it has signed a supply contract with the Tokyo Metropolitan Institute for Geriatrics and Gerontology in Japan for its brain nerve degeneration image analysis software, 'Neurophet AQUA'.
This agreement marks Neurofit's first full-scale entry into the Japanese market and is expected to provide a significant reference point for the company in Japan. Neurofit Aqua performs high-speed quantitative analysis of patients' brain MRIs (magnetic resonance imaging), quantifying indicators such as brain atrophy and white matter degeneration, and provides customized analysis reports for neurodegenerative diseases such as Alzheimer's disease and vascular dementia.
Neurofit's co-CEO, Director Bin Jun-gil, said, "By supplying our software to a Japanese research institute with a competitive edge in Alzheimer's disease research, we have established a bridgehead for entering the Japanese market. We plan to continue expanding our sales channels in Japan using this contract as a springboard."
- See more related articles
You must be logged in to post a comment.